
Pacira BioSciences, Inc.
PCRX
Updated: 05/11/2026, 00:00:39
No historical data available
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
No summaries found.
- Share price
- $36.40
- Market cap
- $1.45B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Frank D. Lee
- Employees
- 827
- IPO date
- 03/02/2011
- Beta
- 0.252
- Last dividend
- $0.00
- Day range
- $36.38 – $36.45
- 52-week range
- $18.80 – $36.67
- 1-day performance
- 0.03%
- 1-year performance
- 93.62%
- Current drawdown (1Y)
- -0.74%
- CIK
- 0001396814
- CUSIP
- 695127100
- ISIN
- US6951271005
- Created
- 07/12/2025, 05:41:57
- Last update
- 05/11/2026, 00:00:39
Track Pacira BioSciences, Inc. with an AI analyst
See which prediction-market events move PCRX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
PRNewsWire • STOCK • 09/06/2026, 19:53:00
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 17:28:29
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
PRNewsWire • STOCK • 01/06/2026, 18:50:00
PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results
GlobeNewsWire • STOCK • 01/06/2026, 11:00:00
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director Nominees
GlobeNewsWire • STOCK • 28/05/2026, 18:20:00
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees
GlobeNewsWire • STOCK • 27/05/2026, 18:20:00
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
GlobeNewsWire • STOCK • 27/05/2026, 10:00:00
PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario
GlobeNewsWire • STOCK • 25/05/2026, 11:27:00
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
GlobeNewsWire • STOCK • 20/05/2026, 08:30:00
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
GlobeNewsWire • STOCK • 13/05/2026, 10:00:00
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
GlobeNewsWire • STOCK • 12/05/2026, 18:01:00
Pacira BioSciences Mails Letter to Stockholders
GlobeNewsWire • STOCK • 05/05/2026, 18:20:00